Artemether + lumefantrine

Generic Medicine Info
Should be taken with food.
Hypersensitivity, history of sudden death or congenital prolongation of QT interval, history of cardiac arrhythmias, bradycardia, CHF with reduced left ventricle ejection fraction, electrolyte disturbances (e.g. hypokalaemia, hypomagnesemia). Concomitant use with strong CYP3A4 inducers, and with drugs known to prolong QT interval.
Special Precautions
Severe renal and hepatic impairment. Children. Pregnancy and lactation. Not indicated for the prevention and treatment of severe or complicated malaria. Patient Counselling This drug may cause dizziness, and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor adequate food consumption during treatment.
Adverse Reactions
Blood and lymphatic system disorders: Anaemia, splenomegaly. Cardiac disorders: Palpitations, QT prolongation. Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea. General disorders and administration site conditions: Asthenia, fatigue, fever, malaise. Hepatobiliary disorders: Hepatomegaly. Infections and infestations: Malaria. Investigations: Increased serum AST. Metabolism and nutrition disorders: Decreased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, chills, myalgia. Nervous system disorders: Dizziness, headache, paraesthesia, clonus, gait disturbance vertigo. Psychiatric disorders: Sleep disorder, insomnia. Respiratory, thoracic and mediastinal disorders: Cough, rhinitis. Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Anaphylaxis.
Drug Interactions
May reduce effectiveness of hormonal contraceptives.
CIMS Class
ATC Classification
P01BE02 - artemether ; Belongs to the class of artemisinin and derivative antimalarials.
Disclaimer: This information is independently developed by CIMS based on artemether + lumefantrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in